Plain-English translation of NCT07183579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study looks at how well burosumab works in children with X-linked hypophosphatemia (XLH), a rare genetic disorder that affects bone health. Researchers want to understand whether starting children on lower doses of this medication can still keep their phosphate levels controlled, rather than always using the standard higher dose. By reviewing medical records from children already treated at specialist centers, the study aims to find out what dose works best for different patients.
Children with XLH have historically had to take multiple medications by mouth that are hard to manage and don't always work well. While this new medication has been transformative for many patients, doctors aren't certain yet whether every child needs the standard recommended dose or whether some do just as well on less—which could mean fewer injections and easier treatment.
You likely qualify if…
You likely don't qualify if…
You won't need to visit a clinic or have new tests done. Instead, researchers at your child's metabolic bone center will review existing medical records from their routine care—including blood tests and phosphate levels already collected over the past year or more. The study team will extract this information to see how well the treatment worked at different doses.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United Kingdom